Severe burn biotech MediWound sets terms for $75 million IPO

By
A A A

MediWound, a biotech developing treatments for severe burns and other hard-to-heal wounds, announced terms for its IPO on Monday. The Yavne, Israel-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, the company would command a fully diluted market value of $326 million. MediWound, which was founded in 2000, plans to list on the NASDAQ under the symbol MDWD. MediWound initially filed confidentially on December 23, 2013. Credit Suisse, Jefferies and BMO Capital Markets are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: MDWD

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

75,031,044
  • $16.26 ▲ 0.31%
64,683,841
  • $99.76 ▲ 2.14%
44,561,744
  • $14 ▼ 6.23%
37,984,130
  • $27.93 ▲ 0.36%
36,148,020
  • $94.39 ▲ 1.49%
33,981,456
  • $22.93 ▼ 1.38%
33,971,527
  • $44.08 ▲ 1.03%
33,685,322
  • $76.95 ▲ 1.32%
As of 10/20/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com